153 related articles for article (PubMed ID: 38191943)
21. An integrated imaging probe design: the synthesis of (99m)Tc/Re-containing macrocyclic peptide scaffolds.
Hickey JL; Simpson EJ; Hou J; Luyt LG
Chemistry; 2015 Jan; 21(2):568-78. PubMed ID: 25388204
[TBL] [Abstract][Full Text] [Related]
22. Thioether Macrocyclic Peptides Selected against TET1 Compact Catalytic Domain Inhibit TET1 Catalytic Activity.
Nishio K; Belle R; Katoh T; Kawamura A; Sengoku T; Hanada K; Ohsawa N; Shirouzu M; Yokoyama S; Suga H
Chembiochem; 2018 May; 19(9):979-985. PubMed ID: 29665240
[TBL] [Abstract][Full Text] [Related]
23. Nitrogen-containing macrocycles having a carbohydrate scaffold.
Potopnyk MA; Jarosz S
Adv Carbohydr Chem Biochem; 2014; 71():227-95. PubMed ID: 25480506
[TBL] [Abstract][Full Text] [Related]
24. A concise route to the macrocyclic core of the rakicidins.
Poulsen TB
Chem Commun (Camb); 2011 Dec; 47(48):12837-9. PubMed ID: 22045383
[TBL] [Abstract][Full Text] [Related]
25. Total syntheses of amythiamicins A, B and C.
Nicolaou KC; Dethe DH; Chen DY
Chem Commun (Camb); 2008 Jun; (23):2632-4. PubMed ID: 18535690
[TBL] [Abstract][Full Text] [Related]
26. In Vitro Selection of Foldamer-Like Macrocyclic Peptides Containing 2-Aminobenzoic Acid and 3-Aminothiophene-2-Carboxylic Acid.
Katoh T; Suga H
J Am Chem Soc; 2022 Feb; 144(5):2069-2072. PubMed ID: 35099961
[TBL] [Abstract][Full Text] [Related]
27. Designed Macrocyclic Peptides as Nanomolar Amyloid Inhibitors Based on Minimal Recognition Elements.
Spanopoulou A; Heidrich L; Chen HR; Frost C; Hrle D; Malideli E; Hille K; Grammatikopoulos A; Bernhagen J; Zacharias M; Rammes G; Kapurniotu A
Angew Chem Int Ed Engl; 2018 Oct; 57(44):14503-14508. PubMed ID: 29908130
[TBL] [Abstract][Full Text] [Related]
28. Cyclic peptide therapeutics: past, present and future.
Zorzi A; Deyle K; Heinis C
Curr Opin Chem Biol; 2017 Jun; 38():24-29. PubMed ID: 28249193
[TBL] [Abstract][Full Text] [Related]
29. Peptide based macrocycles: selective histone deacetylase inhibitors with antiproliferative activity.
Rajak H; Singh A; Dewangan PK; Patel V; Jain DK; Tiwari SK; Veerasamy R; Sharma PC
Curr Med Chem; 2013; 20(14):1887-903. PubMed ID: 23409715
[TBL] [Abstract][Full Text] [Related]
30. Tandem deprotection-dimerization-macrocyclization route to C(2) symmetric cyclo-tetrapeptides.
Ha K; Lebedyeva I; Hamedzadeh S; Li Z; Quiñones R; Pillai GG; Williams B; Nasajpour A; Martin K; Asiri AM; Katritzky AR
Chemistry; 2014 Apr; 20(17):4874-9. PubMed ID: 24700372
[TBL] [Abstract][Full Text] [Related]
31. Cyclic peptide as reference system for b ion structural analysis in the gas phase.
Chen X; Tirado M; Steill JD; Oomens J; Polfer NC
J Mass Spectrom; 2011 Oct; 46(10):1011-5. PubMed ID: 22012667
[TBL] [Abstract][Full Text] [Related]
32. Cyclic peptide production using a macrocyclase with enhanced substrate promiscuity and relaxed recognition determinants.
Alexandru-Crivac CN; Umeobika C; Leikoski N; Jokela J; Rickaby KA; Grilo AM; Sjö P; Plowright AT; Idress M; Siebs E; Nneoyi-Egbe A; Wahlsten M; Sivonen K; Jaspars M; Trembleau L; Fewer DP; Houssen WE
Chem Commun (Camb); 2017 Sep; 53(77):10656-10659. PubMed ID: 28905052
[TBL] [Abstract][Full Text] [Related]
33. Drug discovery: tools and rules for macrocycles.
Heinis C
Nat Chem Biol; 2014 Sep; 10(9):696-8. PubMed ID: 25038789
[No Abstract] [Full Text] [Related]
34. The posttranslational modification cascade to the thiopeptide berninamycin generates linear forms and altered macrocyclic scaffolds.
Malcolmson SJ; Young TS; Ruby JG; Skewes-Cox P; Walsh CT
Proc Natl Acad Sci U S A; 2013 May; 110(21):8483-8. PubMed ID: 23650400
[TBL] [Abstract][Full Text] [Related]
35. Total syntheses and configuration assignments of JBIR-04 and unantimycin A.
Usuki Y; Hamada C; Satoh T
Org Biomol Chem; 2017 Sep; 15(35):7346-7351. PubMed ID: 28829105
[TBL] [Abstract][Full Text] [Related]
36. Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.
Maolanon AR; Kristensen HM; Leman LJ; Ghadiri MR; Olsen CA
Chembiochem; 2017 Jan; 18(1):5-49. PubMed ID: 27748555
[TBL] [Abstract][Full Text] [Related]
37. Peptoid macrocycles: making the rounds with peptidomimetic oligomers.
Yoo B; Shin SB; Huang ML; Kirshenbaum K
Chemistry; 2010 May; 16(19):5528-37. PubMed ID: 20414912
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2005 Oct; 48(20):6229-35. PubMed ID: 16190750
[TBL] [Abstract][Full Text] [Related]
39. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?
Giordanetto F; Kihlberg J
J Med Chem; 2014 Jan; 57(2):278-95. PubMed ID: 24044773
[TBL] [Abstract][Full Text] [Related]
40. Using marine natural products to discover a protease that catalyzes peptide macrocyclization of diverse substrates.
Lee J; McIntosh J; Hathaway BJ; Schmidt EW
J Am Chem Soc; 2009 Feb; 131(6):2122-4. PubMed ID: 19166292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
